Stay ahead of developments in federal and state health care law, regulation and transactions with timely, expert news and analysis.
New FDA guidance will make it easier for generic companies to get drug-device combination products approved.
The final guidance will explain the issues generic applicants should consider when design differences between a generic version of a branded drug-device combination product could impact the clinical effect or safety profile of the generic product, Food and Drug Administration Commissioner Scott Gottlieb said recently.
Gottlieb, who spoke Nov. 28 at the FDA’s Generic Drug Science Day, said as long as the generic applicant can demonstrate that the differences don’t affect the clinical effect or safety profile when the generic is substituted for the branded product, the generic can receive approval.
Drug-device combination products include Mylan Inc.'s allergy treatment EpiPen. Mylan came under attack for increasing the cost of EpiPen by 400 percent in nine years. The company was able to increase the price due to a lack of competing products, and the final guidance will make it easier for generic competition to come to market to help lower prices.
Gottlieb is trying to “take some initiative to foster the availability of generic drugs in this country” and address issues that have blocked generic entry, David Rosen, a partner and public policy lawyer with Foley & Lardner LLP, Washington, who previously held supervisory positions with the FDA, told Bloomberg Law Dec. 5.
The draft version of the guidance was issued in January. It is unclear when the final guidance will be issued.
Sandy Walsh, an FDA press officer, told Bloomberg Law in a Nov. 29 email the agency is reviewing the comments it received on the draft guidance and it will publish the final guidance as soon as possible.
Overall, the draft guidance “does a good job of clarifying the approval pathway for generic drug-device combination products. However, we hope that the final guidance improves on the draft in certain respects,” Bradley Merrill Thompson, general counsel for the combination Products Coalition, an industry group, told Bloomberg Law in a Dec. 5 email.
For example, Thompson said, the FDA should promote a tiered approach based on a risk assessment to determine the impact of the differences between a proposed generic product and the branded product rather than the binary approach described in the draft guidance. The risk assessment could describe the differences as catastrophic, critical, serious, minor, or negligible, he said. The binary approach in the draft describes the differences only as impact or no impact. Thompson also is a Washington-based attorney with Epstein Becker & Green PC and a Bloomberg BNA advisory board member.
Gottlieb said the final guidance will allow a generic product to have certain labeling differences from the branded product if the labeling changes come from permitted design differences. Usually, the labeling for a branded product and a generic product have to be the same.
Thompson said his coalition agrees that this is an important point and thinks “the final guidance should foster a more holistic, risk-based approach with respect to labeling changes, and overall design differences.”
“We understand the reason for FDA’s emphasis on minimizing differences between a generic and reference product; however, this emphasis should not get in the way of innovation and improvements to the design of products and the applicant’s labeling of same,” Thompson said.
But Rosen told Bloomberg Law that allowing labeling differences could cause safety issues. For instance, the EpiPen has very specific instructions on how to use it. If differences in labeling are permitted, a company making a generic product that’s interchangeable with the EpiPen could have slightly different directions for use.
“We have to make sure that there’s no potential for patient confusion, as well as caregiver confusion” if there are differences in the labeling, Rosen said. “What we don’t want, is something that is less safe or less effective than what is currently out there.”
To contact the reporter on this story: Bronwyn Mixter in Washington at email@example.com
To contact the editor responsible for this story: Brian Broderick at firstname.lastname@example.org
The draft guidance is at http://src.bna.com/uFl.
Copyright © 2017 The Bureau of National Affairs, Inc. All Rights Reserved.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)